Metalloproteinase-9 has been suggested as therapeutic target to treat inflammatory bowel disease. Here de Bruynet al. show that genetic and pharmacological inhibition of metalloproteinase-9 does not ameliorate inflammation and fibrosis in mice challenged with acute and chronic colitis protocols.